The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

IV.c

Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

Publications

Hiramatsu K, Ishizuka H, Yamasaki M

Bronchiolar disease associated with gold compounds administration in a patient with rheumatoid arthritis.

Modern rheumatology. 2005;15(2):148-52

Tomioka R, King TE Jr

Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease.

American journal of respiratory and critical care medicine. 1997;155(3):1011-20

Schwartzman KJ, Bowie DM, Yeadon C, Fraser R, Sutton ED, Levy RD

Constrictive bronchiolitis obliterans following gold therapy for psoriatic arthritis.

The European respiratory journal. 1995;8(12):2191-3